Immunohistochemical investigation of the expression of biglycan and integrin beta 1 in melanoma as a prognostic marker for progression-free and overall survival

Immunohistochemical investigation of the expression of biglycan and integrin beta 1 in melanoma as a prognostic marker for progression-free and overall survival - N/A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010086

Enrollment

150

Registered

2016-03-11

Start date

2015-12-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43

Interventions

Group 1: Immunohistochemical staining of biglycan, integrin-beta1 and biglycan related matrix proteins in melanoma tissue

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Availability of archival tumor material of 1. Primary melanoma with good prognosis 2. Primary melanoma with intermediate prognosis 3. Primary melanoma with poor prognosis 4. Primary melanoma with and without sentinel node involvement 5. Melanoma metastases

Exclusion criteria

Exclusion criteria: No archival tumor material available. Follow-up information of outcome parameters not available.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
survival without progression	—

Countries

Germany

Contacts

Public ContactFrank Meiß

Universitätsklinik Freiburg, Dermatologie und Venerologie

frank.meiss@uniklinik-freiburg.de0761 270-67490

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026